Medication overuse headache, or MOH, is one of the most burdensome complications of the world’s most disabling neurological conditions. Migraine affects roughly 1.1 billion people and ranks second globally among causes of years lived with disability. Most patients experience it episodically, but in a subset the attacks grow more frequent until the headache-free baseline erodes entirely. Under the International Classification of Headache Disorders, third edition, MOH is diagnosed when a person with a pre-existing primary headache develops headache on 15 or more days per month while overusing acute medications, triptans, ergots, opioids or combination analgesics on 10 or more days per month, or simple analgesics on 15 or more days per month, for more than three months. It affects roughly 1 to 2.5 percent of adults in the general population, but accounts for 30 to 50 percent of patients presenting with chronic daily headache at specialized centers, and women are affected three to four times more often than men.

Sleep complaints are nearly universal in this population. In cohorts of MOH patients assessed with validated insomnia instruments, prevalence ranges from roughly 38 to 60 percent, and comorbid depression or anxiety is present in approximately 40 to 50 percent of cases. When disordered sleep and MOH coexist, both pain severity and treatment failure rates increase, and even after successful detoxification, one-year relapse rates run between 20 and 40 percent. Understanding why requires examining the direction of the relationship, and that is where the review turns to genetics. Using Mendelian randomization, a technique that employs germline genetic variants as instruments to probe causality, a bidirectional two-sample analysis found that genetic liability to insomnia was significantly associated with migraine risk in both a discovery dataset and an independent validation dataset. The reverse pathway, migraine causing insomnia, showed only a nominal effect that did not replicate, with a confidence interval spanning the null.

The authors are careful about what this genetic evidence can and cannot support. The insomnia instruments were derived from UK Biobank’s single self-reported question about trouble falling or staying asleep, capturing broad insomnia liability rather than formally diagnosed chronic insomnia disorder. More importantly, the migraine instruments were built for migraine broadly defined, not for the MOH transition specifically, which involves analgesic overuse behavior, opioid neuroadaptation and pharmacologically driven sleep disruption that genome-wide association data cannot model. Significant pleiotropy was detected in one validation dataset, and sample overlap between the insomnia and migraine genetic datasets was not corrected for. All causal inferences in the review therefore apply to migraine risk as a proxy, not to the MOH phenotype directly, and the authors call for future genetic studies using cohorts phenotyped strictly by ICHD-3 criteria.

In the opposite direction, the pharmacological evidence is more concrete. Each drug class overused in MOH disrupts sleep through mechanisms intrinsic to its own molecular pharmacology. Opioids suppress orexinergic neuronal firing and truncate slow-wave sleep. Barbiturates and benzodiazepines fragment sleep continuity and suppress REM architecture. Triptans may perturb sleep-related serotonergic pathways, though the clinical significance of chronic effects remains poorly characterized. These are not side effects in any conventional sense; they are direct consequences of engaging the same molecular targets that regulate restorative sleep. Withdrawal studies reinforce this direction of causation: in randomized comparisons and prospective cohorts, patients who achieved medication cessation reported improvements in headache frequency, with parallel gains in self-reported sleep quality described after withdrawal, though sleep was not a pre-specified outcome in the controlled trials.

The mechanistic heart of the review lies in three overlapping neurobiological substrates. The first is the orexin system, a cluster of hypothalamic neurons that project to the periaqueductal gray, the trigeminocervical complex, the rostral ventromedial medulla, the locus coeruleus and the dorsal raphe, structures that each play dual roles in wakefulness maintenance and descending pain inhibition. Animal work shows that selective activation of the orexin 1 receptor attenuates trigeminovascular nociceptive signaling, while blockade amplifies it. The only human biomarker data specific to MOH, however, point in an unexpected direction: in a cerebrospinal fluid study of 30 MOH patients, 27 with chronic migraine and 20 controls, orexin-A was significantly elevated in MOH and correlated positively with both monthly drug intake and substance-dependence scores. Whether this elevation reflects a compensatory antinociceptive response, a stress-induced hypothalamic reaction, or a mechanism tied to drug-seeking behavior remains unresolved, and the authors flag this orexinergic paradox as a key translational question.

The second substrate is melatonin and the circadian system. Melatonin’s nocturnal secretion by the pineal gland serves as the primary timing signal for the circadian clock, and it also carries documented analgesic and anti-inflammatory activity independent of its sleep-promoting effects. Altered circadian signaling has been proposed as a contributor to headache chronification, and genetic variants in CK1δ, a regulator of clock timing, associate independently with both sleep disorders and migraine susceptibility, raising the possibility that some patients carry a constitutive circadian vulnerability predisposing them to both conditions. A single randomized trial of nightly melatonin 3 milligrams showed significant reduction in migraine frequency versus placebo, though whether the mechanism is circadian stabilization, direct analgesia, or both is not established. The third substrate is neuroinflammation: even brief sleep restriction upregulates interleukin-1 beta, tumor necrosis factor alpha and interleukin-6, activates microglia and astrocytes, and impairs the glymphatic clearance of neuroactive metabolites, while chronic analgesic overuse adds a second inflammatory wave through toll-like receptor 4 signaling on glial cells. Together these loops may lower the pain threshold, drive further medication use and fragment sleep in a self-reinforcing cycle.

Sleep architecture itself tells part of the story. During slow-wave sleep, the thalamocortical system dampens sensory relay and raises the pain threshold, while during REM sleep monoaminergic descending inhibition drops to near zero, leaving the nervous system exposed to incoming nociceptive signals. Polysomnographic studies in this population document shortened total sleep time, increased nocturnal arousals, reduced slow-wave sleep duration and diminished slow-wave amplitude, a profile that offers a mechanistically coherent explanation for the morning headaches that characterize the condition. Clinically, the picture is recognizable once one knows to look for it: nearly constant dull pressure that periodically escalates, morning headache on waking, and a non-restorative quality of sleep in which patients wake exhausted regardless of hours in bed. Notably, the insomnia often persists even in patients without overt mood disturbance, suggesting that in at least a subset of cases it reflects primary neurobiological dysregulation rather than simple pain-induced wakefulness.

Two comorbidities compound the problem. Obstructive sleep apnea is substantially more prevalent among chronic migraine patients than in headache-free controls, and when apnea and insomnia coincide, the so-called COMISA phenotype, the resulting subgroup is distinctly harder to treat, with recurrent nocturnal hypoxia providing a trigeminovascular stimulus that medication withdrawal cannot eliminate. Untreated anxiety or depression at baseline similarly predicts poorer detoxification response and higher relapse. Against this backdrop, the authors argue that sequential management, detoxify first, treat sleep later, leaves the insomnia-driven component of central sensitization intact during the most fragile phase of recovery, while behavioral sleep treatment attempted during ongoing analgesic overuse is neutralized by the drugs’ pharmacological disruption of sleep. They propose, explicitly as a hypothesis, that concurrent medication withdrawal, cognitive behavioral therapy for insomnia, preventive pharmacotherapy including anti-CGRP monoclonal antibodies, and CPAP where indicated may outperform sequential care, though no randomized trial has ever tested this.

The review is candid about the gaps that temper its claims. Virtually every withdrawal study measured sleep by questionnaire; no polysomnographic evidence exists that sleep architecture objectively recovers after detoxification, and how recovery might differ across drug classes is unknown. Anti-CGRP antibodies have shown benefit in post-hoc analyses of chronic migraine trials with medication overuse, but none pre-specified sleep endpoints, and dual orexin receptor antagonists, which preserve slow-wave and REM sleep unlike benzodiazepines, carry a directionally uncertain rationale given the paradoxically elevated orexin-A in MOH cerebrospinal fluid. The authors’ prescription is a defined research agenda: a randomized trial of concurrent withdrawal, CBT-I and preventive pharmacotherapy versus detoxification alone, with polysomnographic sleep architecture and one-year relapse as co-primary endpoints. Insomnia in MOH, they conclude, is not a symptom waiting passively for the headache to resolve, but a sustaining mechanism in its own right, and treating it from the outset may prove to be what separates durable remission from repeated cycles of detoxification and relapse.

Subject of Research: The reciprocal neurobiological relationship between insomnia and medication overuse headache

Article Title: Insomnia and medication overuse headache: neurobiological links, reciprocal interactions, and integrated therapeutic strategies

Article References: Cotrik, E., Krymchantowski, A. V., Jevoux, C., Caldas Ferreira, I., Monteiro Auler, L., Ferreira Fontoura Sousa, M. C., & Marcussi, A. P. (2026). Insomnia and medication overuse headache: neurobiological links, reciprocal interactions, and integrated therapeutic strategies. Frontiers in Pain Research, 7, Article 1911261. https://doi.org/10.3389/fpain.2026.1911261

Image Credits: AI Generated

DOI: 10.3389/fpain.2026.1911261

Keywords: medication overuse headache, insomnia, migraine, orexin, melatonin, neuroinflammation, CBT-I, CGRP, sleep apnea, detoxification, Mendelian randomization, central sensitization

The review, led by Abhijit Dutta of India’s Ministry of Ayush and Martin Loef of the University of Witten/Herdecke, together with colleagues from institutions in Switzerland, Canada, Germany, the United Kingdom and Sri Lanka, was conducted according to the Cochrane Handbook and reported under the PRISMA 2020 guidelines. The team searched nine databases, including MEDLINE, EMBASE and CINAHL, along with three trial registries, preprint servers, dissertation archives and even the Indian Ministry of AYUSH research portal, with no language restrictions, running searches through August 2025. From 1,143 identified records, the researchers distilled the evidence down to twelve independent studies: eight randomized controlled trials involving 364 participants and four non-randomized studies of interventions involving 517 more. The studies ranged from four-week pilots to trials with follow-up stretching to six months, and the interventions spanned individualized classical homeopathy, single remedies such as Nux vomica and Coffea cruda, and complex multi-ingredient preparations.

What sets this review apart from earlier syntheses is its methodological ambition. Previous reviews, published more than a decade ago, had concluded that the evidence for homeopathy in insomnia was unconvincing, but they lacked quantitative synthesis and missed recent trials. The new analysis went beyond conventional risk-of-bias assessment using the Cochrane RoB 2 and ROBINS-I tools. It also evaluated whether each trial constituted a fair test of homeopathy as actually practiced, using the MVHT model-validity instrument, rated where each trial sat on the efficacy-to-effectiveness spectrum with the RITES tool, and assessed intervention complexity with an adapted version of the iCAT framework. Certainty of evidence was graded using the GRADE approach, and the data were pooled with random-effects meta-analyses using the Paule-Mandel estimator and Knapp-Hartung confidence intervals. Patient representatives, including six people with lived experience of insomnia, even helped shape the plain language summary.

The headline results are strikingly underwhelming. For sleep quality in adults, a single randomized trial of 30 participants found no statistically significant benefit of individualized homeopathy over placebo, with a mean difference of minus 2.62 points on the Pittsburgh Sleep Quality Index and a confidence interval spanning from minus 5.5 to plus 0.26 — and the certainty of that evidence was rated as low. For total sleep time, three randomized trials comprising 124 participants produced a pooled mean difference of 0.65 hours, or about 39 minutes, in favor of homeopathy, but the confidence interval ran from minus 0.9 to plus 2.2 hours, comfortably crossing the line of no effect. That estimate also carried low certainty and substantial statistical heterogeneity, with an I-squared of 77 percent, meaning the trials disagreed with one another far more than could be explained by chance alone.

There were some glimmers of potential signal. A single randomized trial of 60 participants, judged at low risk of bias, reported a reduction in insomnia severity on the Insomnia Severity Index of 3.2 points, with a confidence interval of minus 5.68 to minus 0.72, rated at moderate certainty. The same trial found an improvement in sleep efficiency of 6.9 points, also at moderate certainty, and a non-significant reduction of 5.6 minutes in sleep-onset latency. In children under six years old with sleep disorders, one open-label randomized trial of 176 participants comparing a homeopathic product against glycine reported a large effect favoring homeopathy, corresponding to an odds ratio of 4.45. But the reviewers rated the certainty of that pediatric evidence as very low, noting that the trial was open-label, industry-funded, and relied on a non-validated, proxy-reported outcome measure — hardly a foundation for clinical recommendations.

The safety picture is equally murky. Only two of the nine studies systematically monitored adverse events. One reported a single mild case of rectal bleeding over a three-month intervention, managed with homeopathic treatment, and the other recorded one case of mild caffeine intolerance. In the pediatric trial, eleven non-serious adverse events were logged, split roughly evenly between groups, with one child discontinuing due to excitability and no serious events observed. The remaining studies either did not monitor or did not report adverse events at all, which means that while nothing alarming emerged, the true frequency of harms simply cannot be estimated. The reviewers rated the certainty of the safety evidence as low to very low.

Beneath the numbers lies a deeper problem: the trials themselves barely resemble one another. Only one randomized trial — the study by Michael and colleagues — achieved both low risk of bias across all outcomes and acceptable model validity, meaning it was both methodologically clean and a fair representation of genuine homeopathic practice. Fewer than half of the trials met the model-validity standard, often because they failed to explain the rationale or principles behind the remedies used. The RITES assessment revealed designs scattered across the entire efficacy-effectiveness spectrum, and the complexity assessment found that half the studies tested single-component interventions while tailoring ranged from none to fully individualized. Only three studies defined their populations using recognized diagnostic standards. Sleep outcomes were overwhelmingly based on subjective diaries and rating scales; just one study used wrist actigraphy and in-home polysomnography, and it appeared only in sensitivity analyses.

The reviewers also probed whether the observed effects were clinically meaningful, not just statistically detectable. For sleep quality, the effect exceeded a proposed minimal important difference of 2.5 points, so the non-null target was retained. But for total sleep time and sleep-onset latency, no established thresholds exist, and published thresholds for insomnia severity are so heterogeneous and population-specific that no definitive adjustment was possible. An exploratory analysis pooling five different sleep outcomes across studies yielded a standardized mean difference of 0.73, nominally significant — but the authors caution that this figure was driven substantially by a single pilot study contributing around half of the meta-analytic weight, and that combining different constructs and scales cannot establish a genuine whole-patient response.

So where does this leave patients and clinicians? The review’s conclusions are unambiguous: the available evidence does not allow firm conclusions about the effects of homeopathy for insomnia, and no reliable evidence demonstrates a specific therapeutic effect. This does not contradict current clinical guidelines, which consistently recommend cognitive behavioral therapy for insomnia as the first-line treatment, backed by a large and coherent evidence base showing durable improvements, while reserving pharmacological options — benzodiazepine receptor agonists and Z-drugs — for selected patients and short-term use, particularly given concerns about tolerance, dependence, residual sedation, and falls and fractures in older adults. At the same time, the authors acknowledge that CBT-I remains underutilized because of access and adherence barriers, which helps explain why patient interest in low-threshold, perceived low-risk complementary approaches remains understandable, even if the evidence does not support positioning homeopathy as an evidence-based alternative or adjunct.

Looking forward, the researchers argue that yet more small, methodologically limited studies would add little. Instead, they call for a rigorously designed, independently conducted confirmatory replication based on the protocol of the single high-quality trial, prospectively registered and reported to CONSORT standards, with systematic adverse-event surveillance, core outcome sets, and explicit reporting of how remedies were selected for different insomnia presentations — difficulty falling asleep, staying asleep, or waking too early. They also suggest comparative effectiveness designs testing homeopathy as an adjunct to established care such as CBT-I, and capturing contextual factors like consultation characteristics and patient expectations. Until such trials exist, the reviewers say, policy decisions about insurance coverage or public health programs should take a cautious and proportionate approach. In the absence of reproducible evidence meeting these standards, the specific therapeutic value of homeopathy for insomnia remains, for now, an open question — one that millions of sleepless people would dearly love to see answered.

Subject of Research: Efficacy and safety of homeopathic treatments for insomnia, assessed by systematic review and meta-analysis

Article Title: Homeopathy for the treatment of insomnia: a systematic review and meta-analysis

Article References: Dutta, A., Sumsuzzman, D. M., Wrzałko, D., van Haselen, R., Weiermayer, P., Gaertner, K., Lakshani, J. A. D. S., Klein, S., Baumgartner, S., & Loef, M. (2026). Homeopathy for the treatment of insomnia: a systematic review and meta-analysis. Frontiers in Sleep, 5, Article 1922807. https://doi.org/10.3389/frsle.2026.1922807

Image Credits: AI Generated

DOI: 10.3389/frsle.2026.1922807

Keywords: homeopathy, insomnia, systematic review, meta-analysis, sleep disorders, sleep quality, randomized controlled trials, GRADE, risk of bias, complementary medicine, CBT-I, adverse events

The study surveyed 124 medical students during a fourth-year examination period, a window of intense psychosocial stress that the researchers deliberately chose to disentangle which factors drive insomnia. Students completed a battery of validated instruments: the Insomnia Severity Index (ISI) as the primary outcome, selected items from the Pittsburgh Sleep Quality Index, the Patient Health Questionnaire-9 for depression, the Generalized Anxiety Disorder-2 scale for anxiety, a visual analogue scale for perceived stress, the Dysfunctional Beliefs and Attitudes about Sleep Scale-16 (DBAS-16), and a reduced Morningness–Eveningness Questionnaire to capture chronotype. Academic performance was also recorded, allowing the team to test whether sleep problems left measurable marks on grades.

The headline number is stark: 46.0 percent of participants, 57 of the 124 students surveyed, scored above the clinical threshold of 10 on the Insomnia Severity Index, indicating symptoms serious enough to warrant attention. That figure is far above the rates typically reported in the general adult population and underscores how vulnerable this group is precisely when their cognitive performance matters most. Insomnia, in the clinical sense, is not simply a few bad nights; it involves difficulty falling asleep, staying asleep, or waking too early, combined with daytime impairment, at least several nights a week.

The objective sleep parameters told a consistent story. Students with clinically relevant insomnia symptoms slept an average of 391.0 minutes per night, about 6.5 hours, with a standard deviation of 76.5 minutes, compared with 438.2 minutes, roughly 7.3 hours, among their peers without significant insomnia, a difference the authors report as statistically significant at P < 0.001. More dramatic still was sleep onset latency, the time it takes to fall asleep: affected students took an average of 51.1 minutes to drift off, versus 21.6 minutes for the rest, again with P < 0.001. Sleep efficiency, the proportion of time in bed actually spent asleep, dropped to 82.2 percent in the insomnia group compared with 90.1 percent in the non-insomnia group.

To understand what was actually driving insomnia severity, the researchers built a multivariable linear regression model that weighed state factors, such as current mood and perceived stress, against trait factors, such as chronotype and sleep-related beliefs. The model performed remarkably well, explaining 57.2 percent of the variance in ISI scores, with an adjusted R² of 0.523. In the adjusted analysis, two variables emerged as independent positive correlates of insomnia severity: depressive symptoms measured by the PHQ-9, with a standardized coefficient of 0.30 and P = 0.01, and dysfunctional beliefs about sleep measured by the DBAS-16, with a coefficient of 0.28 and P < 0.001.

Two variables were inversely associated with insomnia severity. Higher sleep efficiency carried a standardized coefficient of −0.30 with P < 0.001, which is expected, since efficient sleepers by definition have fewer insomnia complaints. More intriguing was the finding that better academic performance was independently linked to lower insomnia severity, with a coefficient of −0.15 and P = 0.037. In other words, students who were performing well academically tended to sleep better, even after accounting for mood, stress, and sleep beliefs, while those whose grades were suffering were more likely to lie awake at night.

Perhaps the most consequential negative result concerns perceived stress, anxiety, and chronotype. Despite the fact that the survey was conducted during an examination period, when stress levels would be expected to peak, none of these three variables remained an independent correlate of insomnia severity once depression and sleep beliefs were taken into account. This challenges the intuitive assumption that exam stress alone explains why students cannot sleep. Instead, the findings suggest that the psychological machinery of insomnia operates through more specific channels: low mood and entrenched, maladaptive cognitions about sleep itself.

The DBAS-16 subscale analysis sharpened this picture further. In a secondary regression model examining the individual subscales of the sleep beliefs questionnaire, which explained 33.2 percent of the variance with an adjusted R² of 0.307, two dimensions stood out: Worry and Helplessness about sleep, and beliefs about the Perceived Consequences of poor sleep. Students who catastrophized about what a sleepless night would do to them, and who felt powerless to control their sleep, scored significantly higher on the insomnia index. This cognitive profile is precisely the target of cognitive behavioral therapy for insomnia, or CBT-I, the first-line treatment for chronic insomnia in adults, which works by restructuring exactly these dysfunctional beliefs and extinguishing the anxiety that keeps sufferers awake.

The researchers frame dysfunctional sleep beliefs as a particularly promising intervention target because they are relatively stable cognitive traits, yet remain amenable to change through structured therapy. Unlike exam schedules or curriculum demands, which are largely fixed features of medical education, sleep-related cognitions can be addressed through screening, psychoeducation, and CBT-I programs delivered by student health services. The authors conclude that sleep health and mental well-being deserve explicit attention within medical education and student health services, a recommendation that carries practical weight given how many students in the sample crossed the clinical threshold.

The study has limitations inherent to its design. As a cross-sectional survey at a single German medical school, it captures associations rather than causal pathways; it cannot determine whether depressive symptoms drive insomnia, whether sleeplessness deepens depression, or whether both feed a common loop. The modest sample of 124 students and the focus on a single examination period also limit generalizability to other institutions, other years of study, and calmer periods of the academic calendar. Nevertheless, the strength of the regression model, the use of validated instruments, and the convergence between subjective insomnia scores and objective sleep parameters lend the findings considerable credibility. For a profession that will spend its career advising patients on healthy sleep, the message that future physicians are themselves at high risk, and that their beliefs about sleep may matter as much as their stress levels, is one that medical educators cannot easily ignore.

Subject of Research: Insomnia prevalence and its psychological and academic correlates among medical students during an examination period

Article Title: Insomnia in medical students during an examination period: associations with depression, dysfunctional sleep beliefs, and academic performance

Article References: Bailer, M., Almazury, K., Sonnauer, F., Sprügel, M. I., Mestermann, S., Utz, J., Kornhuber, J., & Spitzer, P. (2026). Insomnia in medical students during an examination period: associations with depression, dysfunctional sleep beliefs, and academic performance. BMC Medical Education. https://doi.org/10.1186/s12909-026-10565-4

Image Credits: AI Generated

DOI: 10.1186/s12909-026-10565-4

Keywords: insomnia, medical students, sleep disorders, depression, dysfunctional sleep beliefs, academic performance, exam stress, chronotype, Insomnia Severity Index, CBT-I, mental health, medical education

The research team, led by Jessilyn M. Froelich and senior author Yael I. Nillni, recruited 161 pregnant women initiating prenatal care before 28 weeks of gestation at a large safety net hospital in the northeastern United States. The setting matters: safety net hospitals serve populations that often carry a heavier burden of trauma and economic hardship, and postpartum depression is known to strike women from low-income and marginalized backgrounds at elevated rates. Between March 2018 and October 2020, more than 1,300 patients were approached, and the 161 who enrolled completed a baseline psychiatric evaluation before 29 weeks of gestation, followed by three additional assessments during pregnancy and one final visit between five and seven weeks after delivery. At each time point, the women rated their insomnia severity using the Insomnia Severity Index, a validated seven-item questionnaire covering difficulty falling asleep, staying asleep, waking too early, and the daytime distress that poor sleep inflicts.

What set this study apart from earlier work was the rigor of its psychiatric classification. Rather than simply asking women whether they had experienced trauma, the researchers conducted full structured clinical interviews using the Clinician-Administered PTSD Scale for DSM-5 and the Structured Clinical Interview for DSM-5. This allowed them to sort participants into four groups: trauma-exposed women with PTSD, trauma-exposed women with another mental health condition but not PTSD, trauma-exposed women with no current mental health diagnosis, and women with neither trauma exposure nor any current psychiatric condition. The results of that sorting were sobering. More than 83 percent of the sample had experienced at least one potentially traumatic event, 13.2 percent met criteria for PTSD, and another 27.8 percent carried a current mental health diagnosis such as major depressive disorder, substance use disorder, or premenstrual dysphoric disorder.

To trace how sleep changed over time, the team turned to a statistical technique called growth mixture modeling. Unlike conventional approaches that average outcomes across an entire sample, growth mixture modeling searches for hidden subgroups of individuals whose symptoms follow different mathematical curves. The researchers modeled Insomnia Severity Index scores across four pregnancy time points, treating gestational age as a continuous variable with linear growth, and estimated random intercepts and slopes so that each woman could deviate from her group’s average starting point and rate of change. They then compared models containing one, two, three, and four latent classes using the Akaike and Bayesian Information Criteria. The two-class solution won out on parsimony and fit, and it revealed a split the researchers had not fully anticipated.

Roughly 71.5 percent of the women belonged to what the investigators labeled the Normative Sleep class. These participants started pregnancy with relatively low insomnia scores, averaging around 7.2 on the index, and their symptoms drifted slightly, though not significantly, downward over the following months. The remaining 28.5 percent followed a far more troubling course. This Poor Sleep class began pregnancy with subthreshold insomnia, averaging 12.4 points, and then climbed steadily, gaining about 1.55 points per unit of time, until reaching a clinically significant average of 17.1 points by the final weeks of gestation, a level consistent with moderate insomnia. The researchers had hypothesized a third trajectory of consistently poor sleep, but the data told a different story: for a substantial minority of pregnant women, sleep does not merely stay bad, it actively worsens as the body approaches delivery.

The psychiatric groups predicted who landed on which curve. Compared with healthy participants, women with trauma exposure and PTSD had nearly nine times the odds of belonging to the Poor Sleep class, an odds ratio of 8.97 that was statistically significant. Trauma-exposed women with another current mental health condition but no PTSD also faced markedly elevated odds, at 4.07. But here was the study’s most intriguing nuance: women who had experienced trauma yet carried no current psychiatric diagnosis did not differ significantly from trauma-free women, with a non-significant odds ratio of 2.05. Trauma exposure alone, in other words, did not doom a woman to poor sleep. It was the psychological sequelae of trauma, the PTSD, the depression, the anxiety, that set the worsening trajectory in motion. This finding challenges any simplistic view of trauma as a binary risk factor and points instead to underlying vulnerabilities that trauma and psychopathology share.

The link to postpartum depression was equally compelling. When the researchers examined Edinburgh Postnatal Depression Scale scores at the five-to-seven-week postpartum visit, membership in the Poor Sleep class explained roughly 19 percent of the variance in depressive symptoms. Women in the Poor Sleep class averaged 9.26 points on the scale, compared with 4.68 points for the Normative Sleep class, a difference of 4.58 points that was highly significant. While 9.26 falls below the traditional cutoff of 13 for probable postpartum depression, it sits in the range associated with mild depressive symptoms under more flexible scoring interpretations, and it exceeds the threshold of 7 that many clinics use to trigger referral to specialized mental health care. The sleep trajectory, in effect, functioned as an early biomarker of emerging postpartum mood problems.

The biology behind these patterns is likely multifaceted. Sleep is fundamental to emotional regulation and stress reactivity, and insomnia is both a symptom of PTSD and a risk factor for its onset and persistence; between 60 and 90 percent of people with PTSD experience insomnia, and it frequently lingers even after successful PTSD treatment. Recent ecological momentary assessment research has shown that women with PTSD are especially sensitive to sleep loss, with a single bad night amplifying next-day PTSD symptoms. During pregnancy, shifting neuroendocrine signals, rising physical discomfort, and the sleep fragmentation that comes with a changing body may interact with these pre-existing vulnerabilities, creating mutually reinforcing cycles in which poor sleep deepens emotional dysregulation and emotional dysregulation further erodes sleep. Because the psychiatric diagnoses in this study predated the sleep assessments, the researchers are careful to note that causality cannot be established, but the temporal pattern, in which worsening sleep precedes elevated postpartum depressive symptoms, is consistent with the idea that sleep disturbance contributes to, rather than merely reflects, emerging depression.

The clinical implications are hard to ignore. Most pharmacological sleep aids must be used with caution or are outright contraindicated during pregnancy because of potential harm to the developing fetus, which leaves behavioral interventions as the safest option. Cognitive Behavioral Therapy for Insomnia has a strong evidence base in general populations, and the authors argue that integrating it into routine prenatal care could intercept worsening trajectories before they harden into postpartum illness. Because some women’s sleep deteriorates progressively rather than starting out badly, they recommend early and repeated screening for insomnia, trauma exposure, and mental health symptoms across all three trimesters, not just a single check at intake. The study does have limitations, including a modest sample of 151 women in the final analysis, the use of categorical diagnoses that may obscure the compounding effects of comorbidity, and the absence of data on discriminatory obstetric care experiences that can amplify both sleep problems and psychiatric risk. Still, the message is clear and urgent: the road to postpartum depression may be paved months in advance, one restless night at a time, and clinicians who watch a pregnant patient’s sleep closely may catch the danger while there is still time to change course.

Subject of Research: Longitudinal sleep trajectories during pregnancy and their associations with trauma exposure, PTSD, and postpartum depression

Article Title: Sleep trajectories in pregnancy: associations with trauma exposure, PTSD, and postpartum depression

Article References: Froelich, J. M., Stucchi, S. N., Thomas, J. L., Cesare, N., Rasmusson, A. M., Pineles, S. L., & Nillni, Y. I. (2026). Sleep trajectories in pregnancy: associations with trauma exposure, PTSD, and postpartum depression. Journal of Behavioral Medicine. https://doi.org/10.1007/s10865-026-00715-w

Image Credits: AI Generated

DOI: 10.1007/s10865-026-00715-w

Keywords: pregnancy, sleep trajectories, insomnia, PTSD, trauma exposure, postpartum depression, perinatal mental health, growth mixture modeling, prenatal care, CBT-I, maternal health, psychiatry

The letter responds directly to an updated meta-analysis by Barroso and colleagues, published in the same journal, which pooled results from randomized controlled trials of acceptance and commitment therapy for insomnia. Meta-analyses of this kind are considered the highest tier of evidence because they aggregate data across many independent trials, smoothing out the noise of individual studies to reveal whether an effect is real and how large it is. The publication of an updated synthesis is significant because the last wave of ACT-for-insomnia trials had produced a mixed picture, with some studies showing strong benefits and others showing effects that faded or failed to separate from control conditions.

To understand why this matters, it helps to look at the technical anatomy of CBT-I itself. The treatment is not a single technique but a multi-component protocol. Its core is stimulus control, which re-associates the bed with sleep by restricting activities such as reading or worrying in bed, and sleep restriction therapy, which deliberately limits time in bed to consolidate fragmented sleep into a denser, more efficient block. Around this core sit cognitive restructuring, which challenges dysfunctional beliefs about sleep, relaxation training, and sleep hygiene education. Decades of trials, summarized in meta-analyses such as the 2019 review by van der Zweerde and colleagues, show that these effects are durable, persisting for months after treatment ends, and clinical guidelines from the American College of Physicians and the European Sleep Research Society both recommend CBT-I as the first-line treatment for chronic insomnia in adults.

ACT approaches the problem from a different psychological angle. Rather than trying to eliminate unwanted thoughts about sleep, ACT teaches patients to accept the presence of arousal and sleep-related worry without struggling against it, while committing to behaviors aligned with their values regardless of how a given night unfolds. The theoretical rationale is that the effort to control sleep itself, checking the clock, calculating remaining hours, ruminating over the consequences of a bad night, fuels the hyperarousal that keeps insomniacs awake. By defusing from these thoughts and reducing experiential avoidance, ACT aims to break the vicious cycle in which anxiety about sleep produces the very wakefulness it fears.

The question raised by the new meta-analysis is whether this mechanism translates into measurable sleep improvements when ACT is tested on its own. Ballesio’s letter, as its title suggests, answers with a qualified yes. The argument is not that ACT should replace the behavioral core of CBT-I, but that it retains a meaningful role, particularly when integrated with the sleep-scheduling components that have the strongest evidence base. The letter points to a randomized controlled pilot trial by Hertenstein and colleagues published in Psychotherapy and Psychosomatics in 2024, which combined acceptance and commitment therapy with bedtime restriction and compared it against full CBT-I, finding that the hybrid approach was feasible and showed promising signals on both sleep and psychological outcomes.

This matters because insomnia rarely exists in isolation. Large meta-analytic work, including the 2015 JAMA Internal Medicine analysis by Wu and colleagues, has shown that CBT-I improves sleep in people whose insomnia is comorbid with psychiatric and medical conditions, from depression to chronic pain. More recent syntheses, including a 2026 systematic review by Fiori, Lombardo, Baglioni and Ballesio, indicate that treating insomnia with cognitive behavioral therapy also produces long-term benefits for depressive symptoms, suggesting that sleep treatment has ripple effects across mental health. If a substantial subgroup of patients responds better to acceptance-based strategies than to cognitive restructuring, then a one-size-fits-all version of CBT-I may leave therapeutic value on the table.

There is also a biological dimension to the debate. A 2023 meta-analysis by He and colleagues examined CBT-I in patients with the objective short sleep duration phenotype, the subgroup of insomniacs whose polysomnography shows genuinely reduced sleep even as they report severe insomnia. This phenotype is thought to reflect heightened physiological hyperarousal and carries elevated cardiometabolic risk. Acceptance-based interventions, which specifically target autonomic and cognitive arousal rather than sleep-related beliefs alone, are theoretically well suited to this group, and the letter suggests that phenotype-informed treatment selection could become a productive direction for the field.

Access and scalability add a further practical layer. A 2025 debate piece in the journal Sleep by Espie, Grandner and Drake argued that CBT-I can and should be delivered by a broad range of healthcare providers, not only specialized psychologists, because demand vastly outstrips the supply of trained therapists. In that context, the modular structure of insomnia treatment becomes an asset: if acceptance and commitment strategies can be packaged alongside sleep restriction and stimulus control, or offered in digital and group formats, they may extend the reach of effective care. The letter’s intervention can be read as a defense of that flexibility, warning against narrowing the CBT-I umbrella to a single orthodox recipe.

None of this means the evidence for standalone ACT is settled. The letter acknowledges that the updated meta-analysis by Barroso and colleagues tempers some of the earlier enthusiasm, and that trials directly comparing ACT-augmented protocols against gold-standard CBT-I remain scarce, small, and heterogeneous in how they define and deliver the acceptance component. The honest reading of the current literature is that acceptance and commitment therapy is best supported as an adjunct, layered onto the behavioral backbone of insomnia treatment, rather than as a standalone substitute. Ballesio’s argument is essentially a call for precision: the field should stop asking whether ACT works for insomnia in the abstract and start asking for whom, in what combination, and through which mechanisms.

For patients, the practical takeaway is that the conversation about ACT is happening inside a treatment framework that already works well. CBT-I remains the guideline-endorsed first-line therapy, with effects that outlast most pharmacological options and without the dependence risks of hypnotic medication. What the letter adds is a roadmap for making that framework more adaptable, preserving the behavioral techniques with the strongest evidence while leaving room for acceptance-based strategies where hyperarousal, comorbidity, or patient preference call for them. As the field moves toward larger head-to-head trials and phenotype-matched treatment algorithms, the debate over ACT’s place in CBT-I is less a challenge to the standard of care than an attempt to sharpen it.

Subject of Research: The role of acceptance and commitment therapy within cognitive behavioral therapy for insomnia

Article Title: Why we should still ACT in CBT-I

Article References: Ballesio, A. (2026). Why we should still ACT in CBT-I. Journal of Clinical Sleep Medicine, 22(1), Article 187. https://doi.org/10.1007/s44470-026-00206-4

Image Credits: AI Generated

DOI: 10.1007/s44470-026-00206-4

Keywords: insomnia, CBT-I, acceptance and commitment therapy, sleep restriction, meta-analysis, cognitive behavioral therapy, hyperarousal, sleep medicine, psychotherapy, clinical guidelines, randomized controlled trials, mental health

The review, led by Hening Pujasari of Universitas Indonesia together with colleagues in Indonesia and Malawi, followed the PRISMA 2020 reporting guidelines and was prospectively registered with PROSPERO. The team searched ten electronic databases from their inception through October 2025, looking for both randomized and non-randomized studies that assessed sleep outcomes in people living with HIV using validated instruments. Those instruments included the Pittsburgh Sleep Quality Index, the Insomnia Severity Index, actigraphy, and polysomnography—the gold-standard laboratory measurement of sleep architecture. Two reviewers independently screened the records and extracted the data, a standard safeguard against individual judgment errors.

Methodological rigor was a defining feature of the analysis. Risk of bias was assessed with design-appropriate tools: the Cochrane RoB 2.0 instrument for randomized trials and Joanna Briggs Institute tools for other study designs. Importantly, the authors judged bias domain by domain rather than collapsing everything into a single score, which preserves the nuance that a trial might be well-conducted overall yet vulnerable in one specific area such as blinding or outcome measurement. Eleven studies ultimately met the eligibility criteria, spanning a diverse array of interventions and comparison conditions.

That diversity posed a genuine analytical challenge. Because the eleven studies differed substantially in how their comparator groups were structured and which outcome instruments they used, the researchers restricted quantitative pooling a priori to studies with comparable controlled post-intervention Pittsburgh Sleep Quality Index data. Only three randomized trials—by Molavi and colleagues in 2020, Qi and colleagues in 2024, and Wen and colleagues in 2025, together enrolling 187 participants—met that comparability threshold. These were combined using a random-effects model, the standard approach when true effect sizes are assumed to vary across studies rather than being identical.

The pooled result was striking. The standardized mean difference, expressed as Hedges g, came out at −1.38 with a 95 percent confidence interval of −1.78 to −0.99, and heterogeneity was modest at I² = 27.5 percent. In plain terms, the interventions improved subjective sleep quality by an amount conventionally considered large, and the variation between studies was relatively low. Because only three trials were pooled, the team also ran a Hartung-Knapp sensitivity analysis, which is better suited to small numbers of studies than the default methods. That check produced a wider but still statistically significant interval of −2.31 to −0.48, reinforcing confidence in the direction of the effect even under conservative assumptions.

The authors went further with robustness testing. A leave-one-out analysis, in which the pooled estimate is recalculated after omitting each study in turn, retained both the direction and the statistical significance of the effect no matter which single trial was excluded. This is a meaningful safeguard in small meta-analyses, where a single influential study can sometimes drive the entire result. With only three pooled studies, however, publication bias could not be reliably assessed—a limitation the researchers acknowledge explicitly, since small meta-analyses are precisely the setting in which unpublished negative trials are hardest to detect.

Not all the evidence could be pooled. One study used a mixed pharmacological comparator, and several others reported outcomes with instruments other than the Pittsburgh Sleep Quality Index, so these were synthesized narratively rather than merged into the quantitative estimate. This decision reflects a growing consensus in evidence synthesis: forcing heterogeneous studies into a single pooled number can produce a deceptively precise figure that obscures real clinical differences. By pre-specifying their pooling criteria, the authors traded breadth of quantification for integrity of the estimate they did report.

Why does sleep matter so much in HIV care? The review’s background notes that sleep disturbances among people living with HIV are associated with poorer quality of life, suboptimal adherence to antiretroviral therapy, and adverse clinical outcomes. Adherence is particularly critical: consistent daily medication is what keeps viral load suppressed and prevents drug resistance. A patient who sleeps badly may struggle with the energy, mood, and routine organization that adherence demands, creating a pathway from disturbed sleep to worse virological control. Interventions that improve sleep without adding drug interactions or side effects therefore carry substantial public health potential, especially since they are described as scalable and low-risk.

The interventions represented in the eligible studies spanned several categories, including cognitive behavioural therapy for insomnia, brief behavioural treatment for insomnia, mindfulness-based cognitive therapy, emotional freedom techniques, and sleep hygiene training. The authors are careful not to crown a winner: with only three studies in the pooled analysis and considerable heterogeneity in intervention type, no single category can be established as superior. This is an honest reading of the data. Clinicians hoping for a definitive prescription—say, eight sessions of CBT-I over sleep hygiene pamphlets—will not find one here, and the authors explicitly say the findings should be regarded as preliminary pending larger, standardized trials.

What the review does establish is a foundation. It demonstrates that the question is answerable with rigorous methods, that subjective sleep quality as measured by the Pittsburgh Sleep Quality Index responds to non-pharmacological intervention in this population, and that future trials should standardize their outcome instruments and comparator structures so that their results can be combined. For the roughly thirty-eight million people living with HIV worldwide, many of whom report poor sleep, the message is cautiously encouraging: drug-free approaches appear to work, the effect may be large, and the research community now has a clear template for confirming it at scale.

Subject of Research: Non-pharmacological interventions for improving sleep quality in people living with HIV

Article Title: Non-pharmacological interventions to improve sleep quality among people living with HIV: a systematic review and meta-analysis

Article References: Pujasari, H., Putri, Y. S. E., Umar, E., Nurhayati, N., Friska, F., & Mulyana, A. S. (2026). Non-pharmacological interventions to improve sleep quality among people living with HIV: a systematic review and meta-analysis. BMC Public Health. https://doi.org/10.1186/s12889-026-29661-7

Image Credits: AI Generated

DOI: 10.1186/s12889-026-29661-7

Keywords: HIV, sleep quality, non-pharmacological interventions, systematic review, meta-analysis, PSQI, CBT-I, mindfulness, sleep hygiene, public health, antiretroviral therapy, insomnia

The research team, led by Douglas Barroso of the State University of Santa Cruz in Brazil together with co-senior authors Daniel B. Kay of Brigham Young University and Renatha El Rafihi-Ferreira of the University of São Paulo, set out to answer a question that has grown increasingly urgent as insomnia rates climb worldwide. Insomnia disorder, defined by persistent difficulty falling or staying asleep despite adequate opportunity for sleep, affects a substantial proportion of adults across cultures and carries enormous societal costs, from lost productivity to elevated risks of depression and even suicidal behavior. Previous epidemiological surveys in England documented rising insomnia prevalence and increased use of hypnotic medications over fifteen years, underscoring the need for effective, accessible, non-pharmacological treatments.

CBT-I has long been the first-line recommendation in clinical guidelines from the American Academy of Sleep Medicine and the European Sleep Research Society. Its efficacy is well established across dozens of trials and multiple meta-analyses, including studies showing benefits even when insomnia is comorbid with psychiatric and medical conditions or chronic disease. Yet CBT-I has a practical weakness: its core behavioral components, particularly sleep restriction therapy, which deliberately compresses time in bed to rebuild sleep drive, can be demanding and uncomfortable for patients. Research on patient experience has shown that adherence to sleep restriction is a genuine barrier, and studies of treatment-seeking behavior reveal that many people with insomnia never pursue therapy at all. This is where ACT enters the picture with a fundamentally different philosophy.

Acceptance and commitment therapy, developed from the framework of contextual behavioral science, does not attempt to eliminate unwanted thoughts or sensations directly. Instead, it targets experiential avoidance, the struggle to control or escape difficult inner experiences, and cultivates psychological flexibility through acceptance, mindfulness, values clarification, and committed action. Applied to insomnia, ACT encourages patients to stop waging war against wakefulness. Rather than lying in bed monitoring the clock and catastrophizing about tomorrow, patients learn to observe sleep-related thoughts without acting on them and to redirect energy toward what matters in their lives regardless of how a given night unfolds. A influential metacognitive model of insomnia published by Ong, Ulmer, and Manber in 2012 provided the theoretical foundation for this approach, arguing that the effortful struggle to sleep is itself a maintaining factor of the disorder.

To test how well this philosophy translates into clinical outcomes, the researchers conducted a systematic review and meta-analysis following Cochrane Handbook guidance and PRISMA 2020 reporting standards, assessing risk of bias in included trials with the revised RoB 2 tool. They searched three major databases for randomized controlled trials comparing ACT or ACT-based interventions against non-ACT conditions in patients with insomnia. Continuous outcomes were pooled using a restricted maximum likelihood random-effects model in the statistical environment R, a method that accounts for heterogeneity between studies while producing robust combined estimates. The trials encompassed a range of delivery formats, including face-to-face individual and group therapy, telehealth programs enhanced with ACT principles, and internet-delivered self-help interventions for subclinical and clinical insomnia.

The headline result was unambiguous. Compared with waitlist or standard control conditions, ACT produced a standardized mean difference of minus 0.67 in insomnia symptom severity, with a 95 percent confidence interval of minus 1.08 to minus 0.25, a moderate-to-large effect by conventional statistical conventions. In practical terms, patients receiving ACT reported substantially reduced insomnia severity on validated instruments such as the Insomnia Severity Index. Perhaps even more striking were the effects on psychological wellbeing: ACT yielded a small-to-moderate reduction in depression symptoms, with a standardized mean difference of minus 0.34, and a comparable reduction in anxiety symptoms, at minus 0.42, both statistically significant. These secondary outcomes matter enormously, because insomnia and mood disorders are deeply intertwined, with longitudinal evidence suggesting primary insomnia is a risk factor for developing depression.

The direct comparison with CBT-I told a more nuanced story. At posttreatment, there was no significant difference in insomnia severity between the two therapies, with a standardized mean difference of 0.21 favoring CBT-I but with a confidence interval of minus 0.02 to 0.43 that crossed the null. At six-month follow-up the gap narrowed further to a non-significant 0.14. Treatment response rates, defined as a reduction of more than seven points on the Insomnia Severity Index, also did not differ significantly between the therapies. However, one metric did separate them: CBT-I produced significantly higher remission rates at posttreatment, defined as an Insomnia Severity Index score below 8, with a relative risk of 0.81 for ACT, meaning ACT patients were somewhat less likely to achieve full remission by that strict threshold. By follow-up, even this advantage had dissolved into statistical equivalence, with a relative risk of 0.78 and a wide confidence interval of 0.47 to 1.29.

The authors interpret these findings with careful balance. ACT, they conclude, can be an efficacious treatment for insomnia, with particularly strong outcomes for the psychological symptoms that so often accompany sleepless nights. Nevertheless, CBT-I remains the gold standard due to its more extensive and consistent evidence base. This distinction between efficacy and evidentiary maturity is crucial for clinicians and policymakers. CBT-I has accumulated decades of trial data, dose-response evidence showing that more sessions yield better outcomes, and demonstrated effectiveness across primary care settings, group formats, telephone consultations, and digital platforms. ACT for insomnia, by contrast, rests on a smaller but rapidly growing foundation, including recent head-to-head randomized trials in chronic insomnia patients, comparative effectiveness research in women veterans, and pilot studies combining ACT with bedtime restriction.

The implications for clinical practice are nonetheless significant. If ACT matches CBT-I on symptom severity and outperforms it on durability of remission advantage over time, while additionally delivering meaningful relief from depression and anxiety, it offers clinicians a genuine choice in tailoring treatment. Patients who find the demanding behavioral prescriptions of CBT-I unpalatable, or who present with prominent comorbid mood symptoms, may be better suited to an acceptance-based approach. The growing menu of ACT delivery formats, from internet-based self-help to telehealth, also speaks to the pressing problem of treatment access, since most people with insomnia never receive any evidence-based psychological care. As the field moves toward personalized sleep medicine, this updated meta-analysis provides the strongest evidence yet that teaching patients to accept the night, rather than conquer it, is a scientifically legitimate path to better sleep.

Subject of Research: Efficacy of acceptance and commitment therapy compared with cognitive behavioral therapy for insomnia

Article Title: Acceptance and commitment therapy for insomnia: an updated meta-analysis of randomized controlled trials

Article References: Barroso, D., de Paula Portilho, N., Garbacka-Struzik, A., Godoi, D. C., Ellwanger, M. P., Pereira Mendes, T., Alves Ribeiro, V. E., Soares, V. G., Hespanhol, L. C., Siegloch, M. L., Zahran, I. R., Stadler de Abreu, V., de Oliveira, H. M., Peluffo, B., Cerchi, E., Kay, D. B., & Rafihi-Ferreira, R. E. (2026). Acceptance and commitment therapy for insomnia: an updated meta-analysis of randomized controlled trials. Journal of Clinical Sleep Medicine, 22(1), Article 132. https://doi.org/10.1007/s44470-026-00125-4

Image Credits: AI Generated

DOI: 10.1007/s44470-026-00125-4

Keywords: acceptance and commitment therapy, ACT, insomnia, CBT-I, cognitive behavioral therapy, meta-analysis, randomized controlled trials, sleep medicine, psychological flexibility, depression, anxiety, Journal of Clinical Sleep Medicine

The distinction matters because the two conditions demand different treatments. True insomnia is a disorder of hyperarousal, characterized by difficulty falling or staying asleep despite adequate opportunity, and it responds best to cognitive behavioral therapy for insomnia, or CBT-I, and, in some cases, carefully selected hypnotic medications. Obstructive sleep apnea, by contrast, is a mechanical and physiological problem: the upper airway collapses during sleep, oxygen levels dip, and the brain jolts the body awake just enough to reopen the airway. Its first-line treatment is positive airway pressure therapy. If a clinician mistakes apnea-driven fragmentation for insomnia and prescribes a sedative-hypnotic, the underlying breathing disorder may worsen, since hypnotics can suppress the arousal responses and upper-airway muscle tone that protect a vulnerable airway during sleep.

The letter responds directly to a recent analysis of the TURKAPNE cohort, a nationwide Turkish sleep study led by Gürkan and colleagues, which reported that diabetes mellitus is associated with increased prevalence and severity of COMISA. That finding, published in the same journal, seemed to confirm what many clinicians suspected: diabetes and the double burden of insomnia plus apnea travel together. But Xu and colleagues raise a methodological objection that cuts to the heart of how COMISA is diagnosed. Standard insomnia questionnaires, such as the Insomnia Severity Index, ask about difficulty falling asleep, frequent awakenings, and unrefreshing sleep. A patient with severe, untreated sleep apnea will answer yes to nearly all of those questions, not because their brain has forgotten how to sleep, but because their airway keeps waking them up.

This perceptual blind spot is one of the most counterintuitive findings in modern sleep science. Most people with obstructive sleep apnea do not remember the dozens or hundreds of brief arousals that fragment their night. Each arousal lasts only a few seconds, just long enough to restore airflow, and the sleeper typically falls back asleep without forming any memory of the event. What they remember is the consequence: a morning feeling of unrefreshing sleep, daytime fatigue, and the impression that they are an insomniac. When such a patient fills out an insomnia questionnaire, the answers faithfully report the symptom but misattribute the cause. In a population with high rates of obesity and apnea, such as people with type 2 diabetes, that misattribution can inflate the apparent prevalence of true insomnia comorbidity considerably.

The technical solution the letter points toward is objective sleep measurement. Polysomnography, the gold-standard sleep study, records brain waves, eye movements, muscle tone, airflow, respiratory effort, and blood oxygen saturation across a full night. It can quantify the apnea-hypopnea index, the number of breathing interruptions per hour of sleep, and it can reveal whether reported insomnia complaints correlate with objective sleep fragmentation from respiratory events. Studies of Asian patients with comorbid insomnia and sleep apnea, such as the 2025 analysis by Hoc and Lee published in Scientific Reports, have used polysomnographic characteristics to begin separating phenotypes: patients whose insomnia complaints track with respiratory-event-related arousals versus those with genuine difficulty initiating or maintaining sleep independent of breathing disturbances.

The stakes extend well beyond diagnostic bookkeeping. Large epidemiological studies have linked both sleep-disordered breathing and insomnia to cardiometabolic outcomes. The Hispanic Community Health Study/Study of Latinos, analyzed by Li and colleagues in the American Journal of Respiratory and Critical Care Medicine in 2021, found associations between sleep-disordered breathing, insomnia, and incident hypertension and diabetes. If apnea contributes to the development and worsening of diabetes through intermittent hypoxia, sympathetic activation, and impaired glucose metabolism, then misclassifying apnea as insomnia in diabetic patients does more than delay proper treatment; it obscures a potentially modifiable driver of the metabolic disease itself. Treating the apnea could, in principle, improve both sleep and glycemic control, whereas treating a phantom insomnia cannot.

The pharmacological dimension adds further urgency. A 2024 systematic review and meta-analysis by Messineo, Sands, and Labarca in the American Journal of Respiratory and Critical Care Medicine examined how hypnotic medications affect obstructive sleep apnea severity and endotypes. The evidence suggests that the effects of hypnotics on apnea are not uniform: some agents may worsen the disorder by prolonging apneas or blunting arousals, while the impact varies with the patient’s specific apnea endotype, meaning the anatomical and physiological pattern that produces their airway collapse. Prescribing a hypnotic to a diabetic patient whose insomnia symptoms are actually driven by unrecognized apnea therefore carries a real risk of aggravating the very condition that is destroying their sleep, potentially deepening both the sleep fragmentation and the metabolic consequences.

Xu and colleagues propose that studies examining COMISA in diabetes should incorporate objective respiratory monitoring before concluding that insomnia is genuinely comorbid. At minimum, they argue, the diagnostic pathway for a diabetic patient reporting chronic insomnia should include screening for sleep apnea, whether through validated questionnaires such as the STOP-BANG, home sleep apnea testing, or full polysomnography in complex cases. Only after excluding or adequately treating significant sleep-disordered breathing can a clinician confidently diagnose a true insomnia comorbidity and initiate CBT-I or hypnotic therapy on solid ground. This sequencing, they suggest, would sharpen both research definitions and everyday clinical practice, replacing a symptom-based label with a mechanism-based diagnosis.

The letter, which was received on 3 July 2026, accepted on 9 July, and published on 12 August 2026 as article 138 in volume 22 of the journal, was supported by the Gansu Provincial Natural Science Foundation under grant number 25JRRA266. The authors, who work across the departments of nephrology and diabetes, geriatrics, and rehabilitation medicine at Gansu Provincial Hospital of Traditional Chinese Medicine in Lanzhou, declare no competing interests. Their argument is deliberately modest in form but consequential in scope: it does not overturn the TURKAPNE finding, but it reframes it, asking whether the excess COMISA observed in diabetes reflects a true double sleep disorder or an apnea epidemic wearing an insomnia mask.

For the rapidly growing global population of people living with diabetes, the practical message is clear. Chronic insomnia complaints in this group should trigger a search for breathing-related sleep disruption before a diagnosis of comorbid insomnia is accepted and sedatives are prescribed. The tools to make that distinction already exist, from low-cost home sleep testing to full laboratory polysomnography, and the treatments for each condition are fundamentally different. As sleep researchers continue to refine the phenotypes of COMISA, the letter by Xu, Liu, and Liu serves as a reminder that in medicine, as in sleep itself, what appears on the surface is not always what is happening underneath. Getting the diagnosis right may be the first step toward a night of genuinely restorative sleep, and perhaps toward better metabolic health as well.

Subject of Research: Distinguishing true insomnia comorbidity from obstructive sleep apnea-related sleep disruption in patients with diabetes

Article Title: Clarifying COMISA in diabetes: distinguishing true insomnia comorbidity from OSA-related sleep disruption

Article References: Xu, S., Liu, X., & Liu, C. (2026). Clarifying COMISA in diabetes: distinguishing true insomnia comorbidity from OSA-related sleep disruption. Journal of Clinical Sleep Medicine, 22(1), Article 138. https://doi.org/10.1007/s44470-026-00154-z

Image Credits: AI Generated

DOI: 10.1007/s44470-026-00154-z

Keywords: COMISA, insomnia, obstructive sleep apnea, diabetes, sleep medicine, polysomnography, CBT-I, hypnotics, TURKAPNE cohort, sleep fragmentation, type 2 diabetes, sleep-disordered breathing

The study, led by Alexandros Kalkanis and first author Styliani Papadopoulou, employed a structured content-analysis design rather than impressionistic sampling. The researchers selected 127 TikTok videos addressing insomnia management and categorized them by the type of account that produced them: 66 videos came from general users with no stated medical credentials, 20 from physicians, 32 from other healthcare professionals such as nurses, psychologists, or allied health practitioners, and 9 from brand-affiliated accounts, typically promoting commercial sleep products. Each video was then rated with the Global Quality Score, or GQS, a validated five-point instrument widely used in health communication research to grade the educational value of online material. A score of 1 indicates very poor quality with no useful information, while a score of 5 denotes excellent quality grounded in scientific evidence. To capture popularity independently of quality, the team also calculated a Viewing and Engagement Index based on the platforms visible metrics, including views, likes, comments, and shares.

The headline finding is stark. Of the 127 videos analyzed, only 20, or 15.7 percent, demonstrated high educational value, and another 11, or 8.7 percent, reached only moderate quality. In other words, roughly three quarters of the insomnia-related content on the platform fell below the threshold of acceptable educational usefulness. The picture darkens further when the researchers examined specific markers of medical reliability. Just 5 videos in the entire sample were consistent with established clinical guidelines for insomnia, such as those reflected in the European insomnia guideline updated in 2023, which emphasizes cognitive behavioral therapy for insomnia as the first-line treatment. Only 5 videos recommended that viewers consult a physician about their sleep problems, and a mere 2 videos cited any scientific references to support their claims. For a condition affecting a substantial proportion of adults, the near-total absence of guideline-concordant advice is a striking gap between clinical practice and public-facing health information.

Not all content creators performed equally badly, and the gradient of quality tracked closely with professional expertise. Approximately 55 percent of videos produced by physicians achieved a GQS of 3 or higher, indicating at least moderate educational value. That figure dropped to 25 percent for other healthcare professionals, 18 percent for general users, and, perhaps most tellingly, 0 percent for brand-affiliated accounts. Not a single commercially sponsored or brand-associated video in the sample reached acceptable educational quality. The authors also found that sponsored videos were significantly associated with lower-quality content, suggesting that commercial incentives on the platform are actively correlated with degraded information. This pattern echoes a recurring theme in digital health communication research: content designed primarily to sell a product tends to omit the nuance, contraindications, and evidence hierarchy that characterize sound medical advice, while amplifying simplistic claims that lend themselves to engaging short videos.

One of the most consequential findings concerns the disconnect between quality and popularity. The researchers found no correlation between Global Quality Scores and engagement metrics, meaning that videos scoring highly for educational value were no more likely to attract views, likes, or shares than videos rated as poor. This absence of a quality-popularity link matters because TikToks recommendation algorithm is engineered to surface content that generates engagement, not content that is accurate. Prior studies of misinformation have documented similar dynamics, in which emotionally compelling or visually striking material outperforms careful, evidence-based explanations. Applied to insomnia, the implication is that a video promoting an unproven supplement or an anecdotal sleep hack is just as likely, if not more likely, to reach a large audience as a physician summarizing cognitive behavioral therapy, the treatment with the strongest evidence base. The algorithm, in effect, is quality-blind.

The methodological choices of the study deserve attention because they shape how the findings should be interpreted. The Global Quality Score has been validated across numerous platforms and health topics, from YouTube videos on peri-implantitis to online material on psychiatric illness, allowing cross-study comparison. The Viewing and Engagement Index serves as a proxy for real-world reach, though it cannot capture how many viewers act on the advice they see or how long the effect lasts. Because the researchers analyzed publicly released TikTok videos, no ethics review was required, and the dataset reflects what any user searching for insomnia content would plausibly encounter. The authors acknowledge that a snapshot of 127 videos cannot represent the entirety of an ever-shifting platform, where content appears and disappears rapidly and where hashtag rankings vary by region and time. Nevertheless, the consistent pattern across creator categories and the alignment with previous studies of TikTok health content lend the conclusions considerable weight.

The context of prior research makes these results less surprising but more urgent. A 2025 observational study in the Journal of Medical Internet Research documented substantial disinformation about psychiatric illness in TikTok videos, and a cross-sectional analysis in the Journal of Oral Rehabilitation reached similarly pessimistic conclusions about videos on sleep and awake bruxism. Studies of Chinese short-video platforms covering CAR-T cell therapy have likewise shown that popularity does not reflect quality. At the same time, the platform’s influence continues to grow, and the World Health Organization announced a collaboration with TikTok in 2024 aimed at promoting more science-based health information, an acknowledgment by both parties that the information environment on the platform needs deliberate improvement. The new findings suggest that, at least for insomnia, that improvement has not yet materialized at the level of the content users actually watch.

Why does this matter clinically? Insomnia is not a trivial complaint. Chronic insomnia is associated with impaired daytime functioning, increased risk of accidents, worsened mental health outcomes, and elevated healthcare utilization. Clinical guidelines consistently recommend cognitive behavioral therapy for insomnia, or CBT-I, as the first-line intervention, with pharmacological treatment reserved for specific circumstances and generally limited in duration. If people managing insomnia turn first to TikTok and encounter videos that never mention CBT-I, rarely suggest professional evaluation, and frequently promote products without evidence, the platform may delay effective treatment, entreat viewers in unhelpful self-management, or expose them to unnecessary expenditures. The finding that only 2 of 127 videos cited scientific references underscores how rarely creators anchor their claims in the evidence base, leaving viewers with no way to distinguish anecdote from established practice.

The study also carries implications for clinicians and health communicators. The relative advantage of physician-created content suggests that when sleep specialists engage on the platform, they can raise the informational bar, yet their output represented only a small share of the sample and did not dominate engagement metrics. The authors point toward a need for sleep medicine professionals and professional societies to produce accessible, high-quality short-form video content, and for platforms to consider whether engagement-driven ranking should incorporate signals of medical reliability, particularly for health-related topics. Given TikToks behavioral influence on users through algorithmic recommendation, as documented in communication research, the presentation order of content may shape health beliefs as powerfully as the content itself. Absent such interventions, the gap between clinical guidelines and viral advice is likely to persist.

Ultimately, this research letter delivers a quantitative foundation for what sleep clinicians have long suspected anecdotally: TikTok is, at present, a poor source of insomnia management information, and its most-viewed sleep advice cannot be assumed to be its best. For the estimated one in ten adults who meet criteria for an insomnia disorder, and the far larger number who experience occasional sleeplessness, the practical takeaway is caution. Viewers encountering viral sleep tips should treat them as entertainment rather than guidance, look for videos created by identifiable medical professionals, and recognize that none of the brand-promoted content in this study met even minimal educational standards. As short-form video consolidates its role as a first stop for health questions, studies like this one provide the evidence base that policymakers, platforms, and professional societies will need if the information environment is to be repaired rather than merely criticized.

Subject of Research: Medical reliability of insomnia management content on TikTok

Article Title: When sleep advice goes viral: medical reliability of insomnia content on TikTok

Article References: Papadopoulou, S., Karkala, A., Engelshove, E., Testelmans, D., Steiropoulos, P., & Kalkanis, A. (2026). When sleep advice goes viral: medical reliability of insomnia content on TikTok. Journal of Clinical Sleep Medicine, 22(1), Article 162. https://doi.org/10.1007/s44470-026-00163-y

Image Credits: AI Generated

DOI: 10.1007/s44470-026-00163-y

Keywords: insomnia, TikTok, social media, sleep medicine, Global Quality Score, health misinformation, engagement metrics, sponsored content, CBT-I, digital health, sleep disorders, health communication